Procept Biorobotics Corporation · NASDAQ:PRCT

Procept Biorobotics — Investor Day (April 2025)

73 slides from Procept Biorobotics's investor day presentation, Apr 25, 2025

Slide 1: Investor Event 2025 American Urological Association Annual Meeting
© PROCEPT BioRobotics Corporation. All Rights Reserved. Investor Event 2025 American Urological Association Annual Meeting April 25, 2025
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement © PROCEPT BioRobotics Corporation. All Rights Reserved. This presentation and accompanying oral presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT Bi
Slide 3: Agenda
3 © PROCEPT BioRobotics Corporation. All Rights Reserved Introduction Reza Zadno, CEO 1 Hydros & Commercial Update Sham Shiblaq, Chief Commercial Officer 2 Growing My BPH Practice with Aquablation Therapy Dr. Gerald Park 3 Prostate Cancer Introduction Sham Shiblaq, Chief Commercial Officer 4 Prostat
Slide 4: Key Milestones: A Look Back
4 Key Milestones: A Look Back 2021 2022 2023 2024 2025
Slide 5: Key Milestones: A Look Back
5 Key Milestones: A Look Back Medicare reimbursement (APC Level 6) IPO at $1.2B market capitalization 2021 2022 2023 2024 2025
Slide 6: Key Milestones: A Look Back
6 Key Milestones: A Look Back Medicare reimbursement (APC Level 6) IPO at $1.2B market capitalization 2021 Published 5-Year WATER Durability Data1 Expanded Commercial Payor Coverage 2022 1. Canadian Journal of Urology 2023 2024 2025
Slide 7: Key Milestones: A Look Back
7 Key Milestones: A Look Back Medicare reimbursement (APC Level 6) IPO at $1.2B market capitalization 2021 Published 5-Year WATER Durability Data1 Expanded Commercial Payor Coverage 2022 1. Canadian Journal of Urology Published 5-Year WATER II Durability Data1 NICE issued Standard Arrangement in UK
Slide 8: Key Milestones: A Look Back
8 Key Milestones: A Look Back Medicare reimbursement (APC Level 6) IPO at $1.2B market capitalization 2021 Published 5-Year WATER Durability Data1 Expanded Commercial Payor Coverage 2022 1. Canadian Journal of Urology Published 5-Year WATER II Durability Data1 NICE issued Standard Arrangement in UK
Slide 9: Key Milestones: A Look Back
9 Key Milestones: A Look Back Medicare reimbursement (APC Level 6) IPO at $1.2B market capitalization 2021 Published 5-Year WATER Durability Data1 Expanded Commercial Payor Coverage 2022 1. Canadian Journal of Urology Published 5-Year WATER II Durability Data1 NICE issued Standard Arrangement in UK
Slide 11: HYDROS Robotic System
11 HYDROS Robotic System Next-Generation System for Aquablation Therapy AI-Powered Treatment Planning Advanced Image Guidance Robotic Resection Streamlined Workflow © PROCEPT BioRobotics Corporation. All Rights Reserved.
Slide 12: Early Learnings from Hydros Launch
12 Surgeon • Adoption of FirstAssist AI • Training more surgeons per launch Hospital • Lowers cost by eliminating scope sterilization • Increased interest from strategic IDNs to standardize across hospitals • More adoption by low & medium volume hospitals Nursing Staff • Simpler & quicker set-up • S
Slide 13: Significant Opportunity to Penetrate U.S. BPH Market with HYDROS
13 Significant Opportunity to Penetrate U.S. BPH Market with HYDROS 1Q23 vs 1Q25 U.S. Install Base (volume segmentation) 12 4239 172141 333 1Q23 1Q25 547 192 6% 20% 73% 1Q23 8% 31% 61% 1Q25 Low Medium High HYDROS resonates with all BPH hospitals1 Capital sales pipeline represents total BPH hospital
Slide 14: HYDROS is Resonating with All BPH Hospital Segments
14 HYDROS is Resonating with All BPH Hospital Segments HYDROS Launch Driving Market Awareness1 Replacement Cycle Tailwind Starting in 20262 Significant Momentum with Large Strategic IDN Partners 3 Legacy Low/Medium Volume BPH Hospitals are Growing into High Volume BPH Hospitals 4
Slide 15: Growing My BPH Practice with Aquablation Therapy
© PROCEPT BioRobotics Corporation. All Rights Reserved. Growing My BPH Practice with Aquablation Therapy Dr. Gerald Park Partner, Kansas City Urology
Slide 16: Disclosures
16 Disclosures The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of PROCEPT BioRobotics or its subsidiaries. No official endorsement by PROCEPT BioRobotics or any of its subsidiaries of any vendor, products or services contained
Slide 17: Kansas City Urology & Oncology
17 Kansas City Urology & Oncology1 © PROCEPT BioRobotics Corporation. All Rights Reserved 22,300 Annual BPH Patients 1,642 Annual BPH Procedures 8,900 Annual PCa Patients 31 Urologist at Practice 1,051 Annual PCa Procedures (1) Data provided by KCUC
Slide 18: History of BPH Treatment
18 History of BPH Treatment 2020+ • Automation of Aquablation therapy makes average surgeons GREAT • Patients no longer sacrifice safety for efficacy • “I believe Aquablation therapy is only surgical option that will expand the market” 1970s to 2020 • BPH medicines introduced in 1970s – became first
Slide 19: BPH is Anatomical Disease, Best Treated Surgically
19 BPH is Anatomical Disease, Best Treated Surgically TURP Historical gold standard Unpleasant for patient Unpleasant for surgeon Medication Poor efficacy (bladder health) Unsafe (polypharmacy side effects) Long-term side effects emerging Aquablation NEW gold standard Improved Safety + Efficacy Stan
Slide 20: Growing Practice with Aquablation Therapy
20 Growing Practice with Aquablation Therapy1 KCUC Annual BPH Procedures Looking to the Future, I believe • Increased annual volumes by 42% since 2021 • Aquablation will continue to expand surgical market by pulling men off drugs • Automation & Robotics are future of medicine • Aquablation allows su
Slide 21: Dr. Park Annual BPH Procedures
21 Dr. Park Annual BPH Procedures1 Aquablation Doubled Annual Procedures Benefits of Aquablation Therapy Improve operational efficiencies to grow patient volumes Highly reproducible Superior safety outcomes for patients Average procedure time: • Aquablation – 45 min • Laser Enucleation Prostate (LEP
Slide 22: More Objective Evaluation has Increased Conversion Rates
22 More Objective Evaluation has Increased Conversion Rates 2020 Today IPSS Questionnaire Post-Void Residual Test Pressure-Flow Test Volume Study Cysto Evaluation (medical vs surgical) Increased My Surgical Conversion Rates from 10% to 25% © PROCEPT BioRobotics Corporation. All Rights Reserved.
Slide 23: Aquablation Therapy is Efficient
23 Aquablation Therapy is Efficient 0 20 40 60 80 100 120 140 160 180 200 0 50 100 150 200 250 300 TR US In to C a th et er In (m in .) Prostate Size (mL) BPH Procedure Times Aquablation Procedure Time1 1Nguyen DD, et al. Operative time comparison of aquablation, greenlight PVP, ThuLEP, GreenLEP, an
Slide 24: Efficiency Realized: Stacking Cases
24 Efficiency Realized: Stacking Cases1 32 mins 40 mins 25 mins 28 mins 25 mins Prostate Size 127g 142g 126g 77g 104g 07:45 13:50 Procedure © PROCEPT BioRobotics Corporation. All Rights Reserved. (1) Data provided by KCUC
Slide 25: WATER IV PCa: Keys to Success
25 WATER IV PCa: Keys to Success Data Most Interested in Analyzing • Harm reduction • Patient response to treatment option between Active Surveillance & Robotic Prostatectomy What is a Good Clinical Outcome? • Low side effects • Low retreatment rate (i.e. salvage treatment) • No increased metastatic
Slide 26: Prostate Cancer Introduction
© PROCEPT BioRobotics Corporation. All Rights Reserved. Prostate Cancer Introduction SHAM SHIBLAQ Chief Commercial Officer Aquablation therapy for prostate cancer is investigational. Caution: Investigational Device, Limited by Federal (or United States) Law to Investigational Use. Rx Only.
Slide 27: Prostate Cancer in U.S.
27 Prostate Cancer in U.S. Low Risk Intermediate Risk High Risk 210,000 90,000 26% 50% 24% Localized Diagnoses by Risk2 Localized Non-Localized Annual Incidence1 1. American Cancer Society 2024; 2. Rasul et al CUAJ 2020 PROCEPT BioRobotics Corporation. All Rights Reserved 76% Low + Intermediate Risk
Slide 28: Questions for low and intermediate prostate cancer patients
28 Questions for low and intermediate prostate cancer patients How long am I willing to monitor the cancer progression? Question for most cancer patients When can I schedule the surgery? © PROCEPT BioRobotics Corporation. All Rights Reserved. PCa What am I willing to give up to treat the cancer?
Slide 29: Avoid Cancer Progression & Safely Intervene Earlier
29 I N I T I A L D I A G N O S I S 30% Progression at first biopsy1 GOAL: Avoid Cancer Progression & Safely Intervene Earlier benefit risk benefit risk benefit risk benefit risk benefit 60% Eventually undergo radical therapy2 Most men who initiate active surveillance eventually undergo radical thera
Slide 30: BPH and PCa treatment options by prostate size and risk
30 BPH PCa Small (30-40mL) Medium (40-80mL) Large (80-150mL) Extra Large (150mL+) Favorable Intermediate Risk Unfavorable Intermediate Risk P R I O R I T I Z E Symptom Relief Sexual Function & Continence R E S E C T I V E Symptom Relief P R I O R I T I Z E Sexual Function & Continence N O N - R E S
Slide 31: BPH and PCa treatment options by prostate size and risk
31 BPH PCa Small (30-40mL) Medium (40-80mL) Large (80-150mL) Extra Large (150mL+) Favorable Intermediate Risk Unfavorable Intermediate Risk P R I O R I T I Z E Symptom Relief Sexual Function & Continence R E S E C T I V E Symptom Relief P R I O R I T I Z E Sexual Function & Continence N O N - R E S
Slide 32: Prostate cancer is not a focal disease
32 Visible on MRI Not visible on MRI 1. Johnson et al Cancer 2019 Prostate cancer is not a focal disease… a focal treatment is not a viable option 40% of patients with GG2 cancer on one side of the prostate had unidentified GG2 cancer on the other side at final pathology1 © PROCEPT BioRobotics Corpo
Slide 33: Bulk tissue removal in transition and peripheral zones
33 Aquablation therapy for prostate cancer enables bulk tissue removal within the transition and peripheral zones Transition Zone: Obstructive tissue that causes BPH Peripheral Zone: Majority of cancer grows in this tissue © PROCEPT BioRobotics Corporation. All Rights Reserved.
Slide 34: Aquablation Therapy Prostate Cancer Summary
34 Aquablation Therapy Prostate Cancer Summary Today’s Key Message 1 Prostate Cancer is a multi-focal disease that requires a whole gland treatment 3 Aquablation therapy can treat the peripheral zone 2 Strong confidence in WATER IV trial design assumptions 4 60% of Active Surveillance patients will
Slide 35: Disclosures
35 Disclosures The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of PROCEPT BioRobotics or its subsidiaries. No official endorsement by PROCEPT BioRobotics or any of its subsidiaries of any vendor, products or services contained
Slide 36: Localized Prostate Cancer Risk Groups
36 Localized Prostate Cancer Risk Groups NCCN Risk Group PSA Level Grade Group Favorable Intermediate Risk < 10 ng/ml 2 Low Risk < 10 ng/ml 1 Unfavorable Intermediate Risk 10-20 ng/ml 3 High Risk > 20 ng/ml 4 or 5 Ri sk S ca le Cancer grade is a measure of how mutated cells look under microscope The
Slide 37: PCa Treatment Options are Determined by Risk Group
37 PCa Treatment Options are Determined by Risk Group1 Ri sk S ca le Risk Group LOW RISK HIGH RISKINTERMEDIATE NCCN Guidelines Active Surveillance Radiation + Surgery Grade Group GG1 GG2 - GG3 GG4 - GG5 © PROCEPT BioRobotics Corporation. All Rights Reserved. 1. www.nccn.org
Slide 38: Protect: UK Randomized Trial of Monitoring, Radiation & Surgery
38 Protect: UK Randomized Trial of Monitoring, Radiation & Surgery1 Active Surveillance, 545 Prostatectomy, 553 Radiotherapy, 545 1,643 Randomized Patients Through 15 Years Follow-up… Prostatectomy nor radiotherapy reduced mortality >1% compared to surveillance >60% of the surveillance arm underwent
Slide 39: Diagnostic Uncertainty of Prostate Cancer is Substantial
39 Diagnostic Uncertainty of Prostate Cancer is Substantial Prostate Cancer is a Multi-Focal Disease1 1 More cancer is often found, making focal therapy less effective1 mpMRI Guided Biopsy is Best Diagnostic - But is Not Perfect 2 40% of unilaterally diagnosed GG2 is actually bilateral2 3 Surveillan
Slide 40: WATER IV: Aquablation vs. Prostatectomy
40 12-Month Key Secondary Endpoint Ten Year Follow-up with Annual Comparative Analyses 6-Month Endpoint FDA Analysis Co-Primary Endpoints: • Incontinence (pad use) •Erectile Dysfunction Prostatectomy N = 70 Year 10Aquablation N = 210 Long term follow-up will will capture the expected true benefit of
Slide 41: PRCT001 + PRCT002 Update
© PROCEPT BioRobotics Corporation. All Rights Reserved. PRCT001 + PRCT002 Update BARRY TEMPLIN Chief Technology Officer Aquablation therapy for prostate cancer is investigational. Caution: Investigational Device, Limited by Federal (or United States) Law to Investigational Use. Rx Only.
Slide 42: Early Data from PRCT001 + PRCT002
42 Early Data from PRCT001 + PRCT002 n = 22 Grade Group 1-3 BPH + Prostate Cancer patients Enrollment still ongoing Protocol plan up to 125 PRCT001 Global Single Arm Grade Group 1-2 Prostate Cancer Patients Only Enrollment Complete PRCT002 IDE, U.S. Feasibility n = 66 88 Prostate Cancer Patients Tre
Slide 43: PRCT001 + PRCT002 Patient Demographics
43 Age (years old) 67.1 ± 6.4 Region US 77% International 23% Grade-Group GG1 30% GG2 68% GG3 2% Patients with MR v isible lesion (≥PIRADS 3) 81% Percent Patients with IPSS ≥8 92% IPSS 16.3 ± 7.3 PRCT001 + PRCT002 Patient Demographics 70% Prostate Cancer Patients with Intermediate Risk Disease © PRO
Slide 44: PRCT001 + PRCT002 Procedure Details
44 Prostate Vol. Avg (Max Size 133ml) 60.5 ± 25.3 Cancer Location (n=77) Transitional Zone 25% Peripheral Zone 56% Transitional + Peripheral Zone 20% Procedure Duration(min) 66.5 ± 27.8 LOS (days) 1.4 ± 1.1 Cath duration(days) 2.4 ± 2.0 Transfusion % 0.0% PRCT001 + PRCT002 Procedure Details 67 Min A
Slide 45: Radical Prostatectomy Reference Data
45 Radical Prostatectomy Reference Data Comparisons rely on leading, peer-reviewed clinical research in the field of prostate cancer PROTECT TRIAL 1 French Association of Urology (AFU) Trial 2 Urinary & Sexual Impact of RP, TrueNTH 3  NEJM, 2016 Donovan, 2023 Hamdy  Randomized AS, RP, radiation &
Slide 46: Erectile Function vs Radical Prostatectomy
46 17.5 17.1 Baseline 6 months 12 months Aquablation PRCT001 + PRCT002 19.0 6.0 Baseline 6 months 12 months Radical Prostatectomy AFU STUDY2 16.0 4.1 5.5 0.0 5.0 10.0 15.0 20.0 25.0 Baseline 6 months 12 months Radical Prostatectomy PROTECT STUDY1 Erectile Function SH IM S co re 1. Donovon et al NEJM
Slide 47: Urinary Incontinence vs Radical Prostatectomy
47 3 8 Baseline 6 months 12 months Aquablation PRCT001 + PRCT002 4 35 Baseline 6 months 12 months Radical Prostatectomy TrueNTH2 2 46 26 0 10 20 30 40 50 Baseline 6 months 12 months Radical Prostatectomy PROTECT STUDY1 Urinary Incontinence % P ad U se 1. Donovon et al NEJM 2016; 2. Bridge et al Eur
Slide 48: Freedom from Upgrading in MRI era Active Surveillance
48 Freedom from Upgrading in MRI era Active Surveillance UCL London 2 Case Western 1  European Urology, 2020 Donavan, 2023 Stavrinides  mpMRI Era Active Surveillance  (n=672); GG1 = 82% GG2+ = 18% (mpMRI era)  CAUJ, 2022 Omil-Lima  mpMRI Era Active Surveillance  (n=121); GG1 = 90% GG2+ = 10% (
Slide 49: Freedom from Upgrading while on Active Surveillance
49 Freedom from Upgrading while on Active Surveillance 1, Omil-Lima et al CUAJ 2022; 2, Stavrinides et al Eur Urol 2020 © PROCEPT BioRobotics Corporation. All Rights Reserved. Men not treated immediately with radical therapy can remain radical treatment free in absence of progression In contemporary
Slide 50: Freedom from Additional (Salvage) Treatment vs Prostatectomy
50 100 100 3 mo. 6 mo. 9 mo 12 mo. Aquablation PRCT001 + PRCT002 98 96 94 93 3 mo. 6 mo. 9 mo. 12 mo. Radical Prostatectomy AFU STUDY2 97 94 0 20 40 60 80 100 3 mo. 6 mo. 9 mo. 12 mo. Radical Prostatectomy UCSF1 Freedom from Additional (Salvage) Treatment vs Prostatectomy Fr ee do m fr om S al va ge
Slide 51: Preliminary 6-month data shows encouraging progress
51 Preliminary 6-month data shows encouraging progress towards achieving goals Stop or delay progression of cancer Reduce rates of unnecessary morbidity Greater confidence in WATER IV trial design assumptions © PROCEPT BioRobotics Corporation. All Rights Reserved.
Slide 52: Disclosures
52 Disclosures The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of PROCEPT BioRobotics or its subsidiaries. No official endorsement by PROCEPT BioRobotics or any of its subsidiaries of any vendor, products or services contained
Slide 53: Executive Summary
53 Executive Summary Does Not Spread Cancer Highlight clinical data presented to FDA to remove contraindication for BPH Targets Cancer in Peripheral Zone Demonstrate treatment plan to target lesions in the peripheral zone Significantly Slows Cancer Progression 5-year data comparing Aquablation thera
Slide 54: Prostate Cancer is Not A Focal Disease
54 Prostate Cancer is a Not A Focal Disease MISCONCEPTION Aquablation Therapy is Focal Therapy… Aquablation Therapy results in a Near Total Resection of the prostate 1 Waterjet has access to Transitional & Peripheral Zone 2 Ability to resect >95% of all prostate tissue 3 Near Total Resection preserv
Slide 55: Northshore Single Center Aquablation Data
55 Northshore Single Center Aquablation Data1 Group 3 Prostate Cancer Only (Active Surveillance) n= 914 Group 1 BPH Only n= 487 Group 2 BPH + Prostate Cancer n= 53 Is there a difference in BPH symptom improvement Group 2 BPH + Prostate Cancer n= 53 VS. VS. Is there a difference in cancer control © P
Slide 56: Patient Demographics by Cohort
56 Patient Demographics by Cohort1 Men with BPH, BPH+PCa, or PCa only share many similar characteristics © PROCEPT BioRobotics Corporation. All Rights Reserved. Group 1 Group 2 Group 3 Patients BPH Only BPH + PCa PCa Only Sample n=487 n=53 n=914 Age (Years) 69.2 ± 7.8 70.6 ± 6.8 64.4 ± 7.3 PSA (ng/m
Slide 57: BPH vs BPH+PCa – Symptom Relief and Flow Rate
57 BPH vs BPH+PCa – Symptom Relief and Flow Rate1 IPSS IPSS QoL Max Flow Rate (ml/sec) 18.8 10.9 7.7 17.8 8.7 7.3 Baseline 6 weeks 6 months BPH Only BPH + Pca 4.2 2.4 2.0 3.7 1.9 1.2 Baseline 6 weeks 6 months BPH Only BPH + Pca 5.1 17.0 4.5 16.2 PreOp PostOp BPH Only BPH + Pca BPH Efficacy Outcomes
Slide 58: CTC Research Shows No Link to Prostate Cancer Spread
58 CTC Research Shows No Link to Prostate Cancer Spread CTC Shedding & Metastasis • Most tumor cells die within 1-2.5 hours due to immune attack & mechanical stress • Persistent (not transient) shedding increases cumulative probability of metastasis Shredding Patterns: Tumor vs Surgery • Ongoing tum
Slide 59: Aquablation Significantly Slows the Progression of Cancer
59 Aquablation Significantly Slows the Progression of Cancer1 By removing a moderate amount of prostate tissue, Aquablation delayed the natural progression of cancer © PROCEPT BioRobotics Corporation. All Rights Reserved. 30% Progression avoidance at 5 years G G P ro gr es sio n Fr ee P ro ba bi lit
Slide 60: Normal BPH Case: Significant Volume Reduction
60 Normal BPH Case: Significant Volume Reduction Baseline Post-Op Transverse View Sagittal View WATER III data demonstrated Aquablation reduces prostate volume by ~50% © PROCEPT BioRobotics Corporation. All Rights Reserved.
Slide 61: Procedure Evolution to Aquablation for Prostate Cancer
61 Procedure Evolution to Aquablation for Prostate Cancer Baseline Aquablation BPH Aquablation Cancer • Removed obstructive tissue • Expected tissue sloughing • ~50% volume reduction at imaging 3-month follow-up • Removes TZ & PZ • Capsule sparing • Aims to remove >95% of tissue Peripheral Zone Tran
Slide 62: Surgical Treatment Planning and Execution
62 Surgical Treatment Planning and Execution Baseline MRI TRUS Pass 1 Pass 2 Pass 3 Loop removal of residual / remnant tissue Optimized to Access Peripheral Zone © PROCEPT BioRobotics Corporation. All Rights Reserved.
Slide 63: Surgical Case Knowledge
63 Surgical Case Knowledge Baseline 3D MRI Baseline TRUS Tr an sv er se Sa gi tta l Lesions Lesions Surgeon prepares case with insight into lesion location based on MRI & biopsy results Standard BPH procedures will utilize 2 passes without changing mid prostate angle Current prostate cancer techniqu
Slide 67: Final Result: Goal to Remove All Tissue to Capsule
67 Final Result: Goal to Remove All Tissue to Capsule Transverse View Sagittal View FBNC to achieve hemostasis in Sagittal Ultrasound - just like BPH case Under Transverse Ultrasound guidance - remove & resect any residual tissue © PROCEPT BioRobotics Corporation. All Rights Reserved. 1 2
Slide 68: Summary Conclusions
68 Summary Conclusions Cancer Spread Non-Issue Decades of CTC Research Have Not Proven a Causal Link to Metastasis Reduced GG Progression Compelling 5-year data by removing tissue has significant impact on Grade Group progression Peripheral Zone Access More aggressive treatment planning removes >95%
Slide 70: Procept BioRobotics Built on Level Clinical Data
70 Procept BioRobotics Built on Level 1 Clinical Data
Slide 71: Procept BioRobotics Built on Level Clinical Data
71 Procept BioRobotics Built on Level 1 Clinical DataLEGACY PROBLEM Resective Procedures Sacrifice Safety for Efficacy BPH TURP Historical Gold Standard for BPH Surgery 3.3 8.4 18.6 32.3 52.5 2021 2022 2023 2024 2025 U.S. HP Sold (000) < 20% Procedural Market Share in 20252 (1) 2025 financial guidan
Slide 72: Procept BioRobotics Built on Level Clinical Data
72 Procept BioRobotics Built on Level 1 Clinical DataLEGACY PROBLEM Resective Procedures Sacrifice Safety for Efficacy BPH TURP Historical Gold Standard for BPH Surgery 3.3 8.4 18.6 32.3 52.5 2021 2022 2023 2024 2025 U.S. HP Sold (000) < 20% Procedural Market Share in 20252 (1) 2025 financial guidan

PROCEPT BioRobotics — Investor Day (April 2025) on 6ix

Procept Biorobotics — Investor Day (April 2025)

Slide 1: Investor Event 2025 American Urological Association Annual Meeting

Slide 2: Safe Harbor Statement

Slide 3: Agenda

Slide 4: Key Milestones: A Look Back

Slide 5: Key Milestones: A Look Back

Slide 6: Key Milestones: A Look Back

Slide 7: Key Milestones: A Look Back

Slide 8: Key Milestones: A Look Back

Slide 9: Key Milestones: A Look Back

Slide 10: HYDROS System & Commercial Update

Slide 11: HYDROS Robotic System

Slide 12: Early Learnings from Hydros Launch

Slide 13: Significant Opportunity to Penetrate U.S. BPH Market with HYDROS

Slide 14: HYDROS is Resonating with All BPH Hospital Segments

Slide 15: Growing My BPH Practice with Aquablation Therapy

Slide 16: Disclosures

Slide 17: Kansas City Urology & Oncology

Slide 18: History of BPH Treatment

Slide 19: BPH is Anatomical Disease, Best Treated Surgically

Slide 20: Growing Practice with Aquablation Therapy

Slide 21: Dr. Park Annual BPH Procedures

Slide 22: More Objective Evaluation has Increased Conversion Rates

Slide 23: Aquablation Therapy is Efficient

Slide 24: Efficiency Realized: Stacking Cases

Slide 25: WATER IV PCa: Keys to Success

Slide 26: Prostate Cancer Introduction

Slide 27: Prostate Cancer in U.S.

Slide 28: Questions for low and intermediate prostate cancer patients

Slide 29: Avoid Cancer Progression & Safely Intervene Earlier

Slide 30: BPH and PCa treatment options by prostate size and risk

Slide 31: BPH and PCa treatment options by prostate size and risk

Slide 32: Prostate cancer is not a focal disease

Slide 33: Bulk tissue removal in transition and peripheral zones

Slide 34: Aquablation Therapy Prostate Cancer Summary

Slide 35: Disclosures

Slide 36: Localized Prostate Cancer Risk Groups

Slide 37: PCa Treatment Options are Determined by Risk Group

Slide 38: Protect: UK Randomized Trial of Monitoring, Radiation & Surgery

Slide 39: Diagnostic Uncertainty of Prostate Cancer is Substantial

Slide 40: WATER IV: Aquablation vs. Prostatectomy

Slide 41: PRCT001 + PRCT002 Update

Slide 42: Early Data from PRCT001 + PRCT002

Slide 43: PRCT001 + PRCT002 Patient Demographics

Slide 44: PRCT001 + PRCT002 Procedure Details

Slide 45: Radical Prostatectomy Reference Data

Slide 46: Erectile Function vs Radical Prostatectomy

Slide 47: Urinary Incontinence vs Radical Prostatectomy

Slide 48: Freedom from Upgrading in MRI era Active Surveillance

Slide 49: Freedom from Upgrading while on Active Surveillance

Slide 50: Freedom from Additional (Salvage) Treatment vs Prostatectomy

Slide 51: Preliminary 6-month data shows encouraging progress

Slide 52: Disclosures

Slide 53: Executive Summary

Slide 54: Prostate Cancer is Not A Focal Disease

Slide 55: Northshore Single Center Aquablation Data

Slide 56: Patient Demographics by Cohort

Slide 57: BPH vs BPH+PCa – Symptom Relief and Flow Rate

Slide 58: CTC Research Shows No Link to Prostate Cancer Spread

Slide 59: Aquablation Significantly Slows the Progression of Cancer

Slide 60: Normal BPH Case: Significant Volume Reduction

Slide 61: Procedure Evolution to Aquablation for Prostate Cancer

Slide 62: Surgical Treatment Planning and Execution

Slide 63: Surgical Case Knowledge

Slide 64: Treatment Pass #1: Anterior Tissue Focus

Slide 65: Treatment Pass #2: Posterior Tissue Focus

Slide 66: Treatment Pass #3: Further Waterjet Debulking

Slide 67: Final Result: Goal to Remove All Tissue to Capsule

Slide 68: Summary Conclusions

Slide 69: Closing Statements

Slide 70: Procept BioRobotics Built on Level Clinical Data

Slide 71: Procept BioRobotics Built on Level Clinical Data

Slide 72: Procept BioRobotics Built on Level Clinical Data

Slide 73: Thank You